Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity
Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity
复制标题
DOI：
10.3928/15428877-20070501-09
复制
发表时间：
2007-05-01
影响因子：
--
通讯作者：
do Ceu Machado, Maria
中科院分区：
文献类型：
--
作者：
Travassos, Antonio;Teixeira, Susana;do Ceu Machado, Maria
本文描述了三例侵袭性后部早产儿视网膜病变患者玻璃体内注射贝伐单抗的解剖学反应。在所有病例中，最差的眼睛接受单次玻璃体内注射0.75 mg贝伐珠单抗作为单药治疗或激光治疗的补充。24小时内，所有注射眼均显示晶状体图尼卡血管膜消退，虹膜血管充盈，虹膜僵硬消失。此外，加病和视网膜增生开始消退。所有眼睛均不需要额外治疗。长达10个月的随访显示了良好的解剖结局，没有局部或全身不良事件的证据。
The anatomic response to intravitreal bevacizumab injection in three patients with aggressive, posterior retinopathy of prematurity is described. In all cases, the worse eye was treated with a single intravitreal injection of 0.75 mg of bevacizumab as monotherapy or complementary to laser therapy. In 24 hours, all injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment. Follow-up of up to 10 months showed good anatomic outcomes and no evidence of local or systemic adverse events.